Compare Stocks: NVO, SXTPW, ABVC, and ADXN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.98 -2.0%	$0.99	$0.71 ▼ $3.06	$29.10M	0.51	61,027 shs	29,919 shs
ADXN Addex Therapeutics	$2.99 -3.2%	$3.30	$2.56 ▼ $10.43	$3.65M	1.52	6,970 shs	2,233 shs
NVO Novo Nordisk A/S	$40.43 +1.1%	$41.10	$35.12 ▼ $64.16	$178.60B	0.76	10.55 million shs	10.90 million shs
SXTPW 60 Degrees Pharmaceuticals	$0.03 +15.8%	$0.03	$0.02 ▼ $0.15	N/A	N/A	9,304 shs	2,214 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	-3.85%	-0.99%	-3.85%	-64.29%
ADXN Addex Therapeutics	0.00%	+3.70%	+0.33%	-47.34%	-66.19%
NVO Novo Nordisk A/S	0.00%	+2.34%	+7.10%	-15.19%	-19.11%
SXTPW 60 Degrees Pharmaceuticals	0.00%	-0.38%	-6.50%	+2.78%	-52.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.98 -2.0%	$0.99	$0.71 ▼ $3.06	$29.10M	0.51	61,027 shs	29,919 shs
ADXN Addex Therapeutics	$2.99 -3.2%	$3.30	$2.56 ▼ $10.43	$3.65M	1.52	6,970 shs	2,233 shs
NVO Novo Nordisk A/S	$40.43 +1.1%	$41.10	$35.12 ▼ $64.16	$178.60B	0.76	10.55 million shs	10.90 million shs
SXTPW 60 Degrees Pharmaceuticals	$0.03 +15.8%	$0.03	$0.02 ▼ $0.15	N/A	N/A	9,304 shs	2,214 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	-3.85%	-0.99%	-3.85%	-64.29%
ADXN Addex Therapeutics	0.00%	+3.70%	+0.33%	-47.34%	-66.19%
NVO Novo Nordisk A/S	0.00%	+2.34%	+7.10%	-15.19%	-19.11%
SXTPW 60 Degrees Pharmaceuticals	0.00%	-0.38%	-6.50%	+2.78%	-52.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
NVO Novo Nordisk A/S	2.00	Hold	$59.44	47.02% Upside
SXTPW 60 Degrees Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVO, SXTPW, ABVC, and ADXN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Market Perform	$47.00 ➝ $40.00
10/9/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
10/8/2026	NVO Novo Nordisk A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C-) ➝ Sell (D+)
10/2/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/29/2026	NVO Novo Nordisk A/S	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform
9/29/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell
9/22/2026	NVO Novo Nordisk A/S	Cfra Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Sell	$38.00
9/21/2026	NVO Novo Nordisk A/S	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
9/21/2026	NVO Novo Nordisk A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
9/21/2026	NVO Novo Nordisk A/S	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
9/21/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy ➝ Neutral

(Data available from 11/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	51.29	N/A	N/A	$0.52 per share	1.88
ADXN Addex Therapeutics	$210K	17.52	N/A	N/A	$4.67 per share	0.64
NVO Novo Nordisk A/S	$329.43B	0.55	$4.95 per share	8.17	$6.58 per share	6.14
SXTPW 60 Degrees Pharmaceuticals	$1.11M	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	11/16/2026 (Estimated)
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-174.44%	-126.47%	11/9/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	9.89	11.82	1.30	35.36%	58.61%	20.91%	11/4/2026 (Estimated)
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest NVO, SXTPW, ABVC, and ADXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/16/2026	Q3 2026	ABVC ABVC BioPharma	-$0.40	N/A	N/A	N/A	$0.11 million	N/A
11/4/2026	Q3 2026	NVO Novo Nordisk A/S	$0.7310	N/A	N/A	N/A	$11.08 billion	N/A
9/25/2026	Q2 2026	ADXN Addex Therapeutics	N/A	-$1.48	N/A	-$1.48	N/A	$0.01 million
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
NVO Novo Nordisk A/S	$0.81	2.00%	+21.74%	19.80%	N/A
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest NVO, SXTPW, ABVC, and ADXN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.07
ADXN Addex Therapeutics	N/A	0.76	0.76
NVO Novo Nordisk A/S	0.55	0.87	0.66
SXTPW 60 Degrees Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ADXN Addex Therapeutics	16.14%
NVO Novo Nordisk A/S	11.54%
SXTPW 60 Degrees Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ADXN Addex Therapeutics	15.00%
NVO Novo Nordisk A/S	0.07%
SXTPW 60 Degrees Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	19	26.69 million	21.62 million	Optionable
ADXN Addex Therapeutics	3	1.23 million	1.05 million	Not Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
SXTPW 60 Degrees Pharmaceuticals	3	N/A	N/A	Not Optionable

NVO, SXTPW, ABVC, and ADXN Headlines

Recent News About These Companies

60 Degrees reports promising babesiosis cure in study

October 27, 2026 | tipranks.com

60 Degrees Pharmaceuticals Reports Positive Clinical and Molecular Results for Tafenoquine in Expanded Access Babesiosis Study

October 27, 2026 | quiverquant.comQ

60 Degrees highlights interim tafenoquine data, caps enrollment

October 6, 2026 | tipranks.com

60 Degrees Pharmaceuticals to Conclude Enrollment in Severe Babesiosis Trial, Plans January 2027 Unblinding and FDA Meeting

October 6, 2026 | quiverquant.comQ

60 Degrees Advances Babesiosis Treatment With FDA Submission

September 14, 2026 | tipranks.com

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026 | quiverquant.comQ

60 Degrees Pharmaceuticals Reports Second Quarter 2026 Financial Results with 106% Increase in Net Product Revenues

August 14, 2026 | quiverquant.comQ

60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions

August 6, 2026 | tipranks.com

60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital

August 4, 2026 | tipranks.com

60 Degrees Pharmaceuticals Announces $1.0 Million Private Placement of Common Stock and Warrants

July 30, 2026 | quiverquant.comQ

60 Degrees updates strategy for ARAKODA and profitability

July 20, 2026 | tipranks.com

Interim Trial Plan Finalized for Tafenoquine Babesiosis Study

July 9, 2026 | tipranks.com

60 Degrees details tafenoquine priority review voucher strategy

June 3, 2026 | tipranks.com

60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria Prevention

April 15, 2026 | quiverquant.comQ

60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational Developments

March 31, 2026 | quiverquant.comQ

60 Degrees Updates Affiliate Share Ownership Disclosure Error

March 20, 2026 | tipranks.com

60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering

March 13, 2026 | tipranks.com

60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status

February 12, 2026 | tipranks.com

GoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria Prevention

February 2, 2026 | quiverquant.comQ

60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal

January 23, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVO, SXTPW, ABVC, and ADXN Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$0.98 -0.02 (-1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.19%)

As of 07:30 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Addex Therapeutics NASDAQ:ADXN

$2.99 -0.10 (-3.24%)

As of 04:00 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Novo Nordisk A/S NYSE:NVO

$40.43 +0.43 (+1.08%)

Closing price 03:59 PM Eastern

Extended Trading

$40.40 -0.03 (-0.06%)

As of 07:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.03 +0.00 (+15.83%)

As of 10:40 AM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVO, SXTPW, ABVC, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVO, SXTPW, ABVC, and ADXN Earnings

Compare Dividends

Latest NVO, SXTPW, ABVC, and ADXN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVO, SXTPW, ABVC, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVO, SXTPW, ABVC, and ADXN Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Addex Therapeutics NASDAQ:ADXN

Novo Nordisk A/S NYSE:NVO

60 Degrees Pharmaceuticals NASDAQ:SXTPW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools